Literature DB >> 19756945

The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.

Carla Ghelardini1, Nicoletta Galeotti, Elisa Vivoli, Irene Grazioli, Carla Uslenghi.   

Abstract

A hypofunctionality of Gi proteins has been found in migraine patients. The fixed combination of indomethacin, prochlorperazine and caffeine (Indoprocaf) is a drug of well-established use in the acute treatment of migraine and tension-type headache. The aim of this study was to investigate if Indoprocaf was able to exert its central antinociceptive action when Gi proteins activity is abolished by pertussis toxin (PTX), compared to its single active ingredients and to sumatriptan. The mice model of abdominal constriction test induced by an i.p. injection of a 0.6% solution of acetic acid was used. The study showed that Indoprocaf (a fixed combination of indomethacin 1 mg/kg, prochlorperazine 1 mg/kg and caffeine 3 mg/kg, s.c.) and sumatriptan (20 mg/kg, s.c.) exert their central antinociceptive action independently from the Gi proteins. In addition, the antinociceptive efficacy of Indoprocaf in this study was statistically superior to that of sumatriptan. This study also showed that the single active ingredients of Indoprocaf, indomethacin (1 mg/kg, s.c.), prochlorperazine (1 mg/kg, s.c.) and caffeine (3 mg/kg, s.c.), were able to exert their central antinociceptive action independently from the Gi proteins. However, Indoprocaf at analgesic doses was able to abolish almost completely the abdominal constrictions, with a statistically higher efficacy compared to the single active ingredients, showing an important synergic effect of Indoprocaf. This synergic effect was evident not only when Gi proteins activity was abolished by PTX, but also under control condition, when Gi proteins were active. This study suggests that the central antinociceptive action induced by antimigraine drugs is independent from Gi proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756945      PMCID: PMC2778775          DOI: 10.1007/s10194-009-0151-1

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  30 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  A reduced functionality of Gi proteins as a possible cause of fibromyalgia.

Authors:  N Galeotti; C Ghelardini; M Zoppi; E D Bene; L Raimondi; E Beneforti; A Bartolini
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

3.  Generalized hyperalgesia in patients with chronic tension-type headache.

Authors:  S Ashina; L Bendtsen; M Ashina; W Magerl; R Jensen
Journal:  Cephalalgia       Date:  2006-08       Impact factor: 6.292

4.  Hypofunctionality of Gi proteins as aetiopathogenic mechanism for migraine and cluster headache.

Authors:  N Galeotti; C Ghelardini; M Zoppi; E Del Bene; L Raimondi; E Beneforti; A Bartolini
Journal:  Cephalalgia       Date:  2001-02       Impact factor: 6.292

Review 5.  A benefit-risk assessment of caffeine as an analgesic adjuvant.

Authors:  W Y Zhang
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  Acute migraine therapy: recent evidence from randomized comparative trials.

Authors:  Anna Mett; Peer Tfelt-Hansen
Journal:  Curr Opin Neurol       Date:  2008-06       Impact factor: 5.710

7.  Indomethacin, caffeine and prochlorperazine alone and combined revert hyperalgesia in in vivo models of migraine.

Authors:  Nicoletta Galeotti; Carla Ghelardini; Irene Grazioli; Carla Uslenghi
Journal:  Pharmacol Res       Date:  2002-09       Impact factor: 7.658

8.  Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial.

Authors:  Vincenzo Di Monda; Maria Nicolodi; Antonina Aloisio; Pierluigi Del Bianco; Marco Fonzari; Irene Grazioli; Carla Uslenghi; Leonardo Vecchiet; Federigo Sicuteri
Journal:  Headache       Date:  2003-09       Impact factor: 5.887

9.  Prochlorperazine induces central antinociception mediated by the muscarinic system.

Authors:  Carla Ghelardini; Nicoletta Galeotti; Carla Uslenghi; Irene Grazioli; Alessandro Bartolini
Journal:  Pharmacol Res       Date:  2004-09       Impact factor: 7.658

10.  Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study.

Authors:  G Sandrini; R Cerbo; E Del Bene; A Ferrari; S Genco; I Grazioli; P Martelletti; G Nappi; L Pinessi; P Sarchielli; P Tamburro; C Uslenghi; G Zanchin
Journal:  Int J Clin Pract       Date:  2007-08       Impact factor: 2.503

View more
  2 in total

Review 1.  Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.

Authors:  Sheridan M Hoy; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 2.  Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?

Authors:  Andreas Straube; Bernhard Aicher; Bernd L Fiebich; Gunther Haag
Journal:  BMC Neurol       Date:  2011-03-31       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.